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Abstract
Background
The inflammatory biomarkers, YKL-40 and interleukin-6 (IL-6), are elevated in patients with
metastatic colorectal cancer. We examined their associations with relapse-free survival
and overall survival in combination with serum C-reactive protein (CRP), carcinoembryonic
antigen (CEA), and carbohydrate antigen 19–9 (CA19-9) in patients with colorectal liver
metastases.
Methods
Altogether 441 consecutive patients undergoing liver resection at Helsinki University Hospi-
tal between 1998 and 2013 were included in the study. Pre- and postoperative YKL-40 and
IL-6 were determined from serum samples with commercially available enzyme-linked
immunosorbent assay (ELISA) kits, and CRP, CEA, and CA19-9 by routine methods. Asso-
ciations between these biomarkers and relapse-free and overall survival were examined
using Cox regression analysis.
Results
Patients with 2–5 elevated biomarkers were at an increased risk of relapse compared to
those with 0–1 elevated biomarkers, preoperatively (HR 1.37, 95% CI 1.1–1.72) or postop-
eratively (HR 1.54, 95% CI 1.23–1.92). Patients with 2–5 elevated biomarkers were also at
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an increased risk of death compared to those with 0–1 elevated biomarkers, preoperatively
(HR 1.76, 95% CI 1.39–2.24) or postoperatively (HR 1.83, 95% CI 1.44–2.33).
Conclusion
The results suggest that a protein panel of the inflammatory biomarkers YKL-40, IL-6, and
CRP, and the cancer biomarkers CEA and CA19-9 might identify patients that benefit from
more aggressive treatment and surveillance, although the additional value of IL-6 and CRP
in this aspect is limited.
Introduction
In 2018, more than 860 000 patients died from colorectal cancer (CRC) worldwide [1]. A large
number, up to 75%, of patients with CRC develop colorectal liver metastases (CRLM) [2]. If
the metastases are confined to the liver and other resectable extrahepatic sites, resection with
curative attempt is recommended, if technically and physiologically feasible [3]. Five- and ten-
year survival rates after liver resection have been in the range of 38% and 26%, respectively,
but a significant number of the resected experience an early recurrence [3]. As relapses are fre-
quent and median overall survival (OS) short (median 3.6 years in a review), prognostic scor-
ing systems have been developed for identifying patients who might benefit from intensified
adjuvant therapy and follow-up, combined with a possible re-resection upon recurrence [3–5].
A well-defined, universally accepted adjuvant therapy and surveillance regimen after liver
resection is yet to be established for this patient group.
Serum carcinoembryonic antigen (CEA) is widely used as a biomarker for detection of
recurrent CRC and for monitoring the response to systemic therapy [6], but its prognostic
value leaves room for improvement and added arsenal, as around 20% of CRC tumors are
CEA negative [7]. Carbohydrate antigen 19–9 (CA19-9), also called sialyl-LewisA, is a tetrasac-
charide carbohydrate synthesized by the gastrointestinal epithelium. Several studies have
shown that elevated CA19-9 levels were strong negative prognostic factors in different stages
of CRC [8, 9]. Finding new biomarkers in addition to CEA and CA19-9 would help estimate
the risk of recurrence and determine a suitable adjuvant therapy and follow-up protocol for
patients with metastatic CRC (mCRC) after liver resection.
Tumor-promoting inflammation is an enabling characteristic of cancer and enhanced sys-
temic inflammatory response has been linked to impaired survival [10, 11]. Inflammatory bio-
markers are of special interest in the search for new valuable prognostic biomarkers on top of
established pathologic and demographic factors in patients resected for CRLM. Serum C-reac-
tive protein (CRP), YKL-40 (also called chitinase-3-like-1 protein, CHI3L1) and interleukin-6
(IL-6) are established biomarkers of inflammation [9, 12, 13]. In a recent study, serum C-reac-
tive protein (CRP), the production of which is stimulated by IL-6 [14], was found to be signifi-
cantly associated with shorter OS in patients undergoing liver resection [15]. IL-6 and YKL-40
are secreted by cancer cells and macrophages [12, 16], and the latter also by neutrophils [12].
YKL-40 could play an important role in promoting tumor metastasis and impairing survival
via multiple mechanisms, such as upregulating the secretion of matrix metalloproteinases, acti-
vating the TGFβ pathway [17], inducing angiogenesis via its receptor IL-13α2 and membrane
protein TMEM219, and binding to RAGE (receptor for advanced glycation end products)
[12]. IL-6 stimulates the production of YKL-40 and angiogenesis via its receptors IL-6R and
sIL-6R [12, 18–20]. Elevated serum YKL-40 and IL-6 levels are seen in patients with diagnosed
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CRC or those later developing gastrointestinal cancers [13, 21], and higher levels are linked to
impaired survival [12, 15].
The early detection of cancer with emerging technologies, such as liquid biopsies that
enable the detection of circulating tumor cells, cell-free DNA (cfDNA) or circulating tumor
DNA (ctDNA) with specific mutations in blood or other body fluids, is under active investiga-
tion [22]. However, protein biomarkers are at present an integral part of clinical work and
may be more easily accessed.
In this retrospective biomarker study, we examined the prognostic value of preoperative
and postoperative serum YKL-40, IL-6, CRP, CEA, and CA19-9 in a cohort of 441 consecutive
patients who had undergone liver resection for CRLM. Our hypothesis was that the patients
with combined high serum concentrations of YKL-40, IL-6, CRP, CEA, and CA19-9 would
have the worst relapse-free survival (RFS) and OS in patients with mCRC treated with cura-
tive-intent liver resection.
Materials and methods
Patients
Altogether 455 consecutive patients undergoing liver resection for mCRC were enrolled in this
study between March 1998 and February 2013 at the Helsinki University Hospital, Helsinki,
Finland (S1 Fig). All patients included were diagnosed with resectable CRLM, and those with
possible other malignancies were excluded. Liver metastases were defined as synchronous, if
they were diagnosed at the same time or within 6 months after the operation of the primary
tumor, and as metachronous, if diagnosed later. The liver resections were considered major if
more than two Couinaud segments were resected. Extrahepatic disease was excluded with
whole-body contrast-enhanced computed tomography (CT) and in some cases with positron
emission tomography (PET). Neoadjuvant and/or adjuvant treatment were given according to
guidelines at the time of surgery. Fourteen patients were excluded from the statistical analyses
due to the following reasons: 7 patients had extrahepatic metastases that eventually could not
be surgically removed, in 6 cases a radical liver resection could not be performed, and 1 patient
died within 20 days after surgery, and thus, the prognostic value of the serum markers could
not be evaluated.
Serum samples were taken before liver resection and approximately 3 months after opera-
tion. Median time from preoperative blood sampling to surgery was 16 days (interquartile
range (IQR) 9–29 days). Median time from surgery to postoperative sampling was 94 days
(IQR 89–98 days).
The study was conducted in accordance with the Declaration of Helsinki, and it was
approved by the Ethics Committee at Helsinki University Hospital (IRB99/07/01, HUS531/E6/
01, HUS460/E6/05, HUS323/13/3/2008, HUS242/13/03/02/2011). Collection and analysis of
blood samples were approved by the National Supervisory Authority for Welfare and Health
(Valvira) of Finland (STM Dno 4858/04/047/08), and information about the dates of death
was obtained from the Central Statistical Office of Finland (TK-53-1004-9). A verbal informed
consent was obtained from all the patients included in the study, and the collection of the
research samples signified consent. The collection of blood samples was initiated over twenty
years ago, and written consent was not required at that time according to the Finnish law. The
REMARK guidelines have been used in reporting [23].
Serum samples
The pre- and postoperative venous blood samples were collected in gel tubes. The samples
were centrifuged within 30–120 minutes, and serum was stored at -80˚C. YKL-40 and IL-6
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were determined in duplicate in both pre- and postoperative serum samples using commer-
cially available enzyme-linked immunosorbent assays (ELISAs); YKL-40: MicroVue YKL-40
ELISA (Catalog #8020), Quidel Corporation, San Diego, CA, USA; and IL-6: Quantikine
HS600B, R&D Systems, Abingdon, OX, UK; according to the manufacturer’s instructions. For
YKL-40, the detection limit was 20 ng/ml, and intra- and inter-assay coefficients of variation
(CVs) <5% and<6% [24]. For IL-6, the detection limit was 0.01 pg/ml, and intra- and inter-
assay CVs�8% and�11% [25]. The pre- and postoperative serum levels of CRP, CEA and
CA19-9 were determined with automatic analyzers as follows: CRP: immunoturbidimetric
method (1998–2013) at Huslab laboratories, Helsinki University Hospital; CEA and CA19-
9: immunoenzymatic assay, Bayer Immuno 1 (CEA: 1998–10/2005; and CA19-9: 1998–1/
2006), or immunochemiluminometric assay, Abbott Architect (CEA: 10/2005–2013; and
CA19-9: 1/2006–2013). All measurements were performed by technicians blinded to the study
endpoints.
An age-corrected 95th percentile for serum YKL-40 in healthy individuals served as the cut-
off level for elevated values, and it was calculated using the formula proposed by Bojesen et al.
[24]:
Pi% ¼
100
ð1þ YKL   40  3 � ð1:062AgeÞ � 5000
The cut-off values for the other biomarkers were the following: 4.95 pg/ml (P95% for serum
IL-6 in healthy individuals [25]); 5 mg/l for CRP; 5 μg/l for CEA; and 37 kU/l for CA19-9.
Statistical analyses
Wilcoxon signed-rank test was used for estimating differences between pre- and postoperative
serum values and Spearman’s rank test for testing correlations. For OS, the time to event was
defined as time from the date of liver surgery to the date of death from any cause or censored
at the end of follow-up, and for RFS as time from surgery to recurrence or censored at the end
of follow-up. The cut-off date for follow-up was October 31st, 2017.
Serum YKL-40, IL-6, CRP, CEA, and CA19-9 were included in the Cox regression analyses
as log2-transformed continuous variables due to non-normality and as elevated or normal val-
ues according to the above-mentioned cut-off levels in the Kaplan-Meier plots. Biomarker val-
ues below the limit of detection (LOD) were imputed as LOD/2 as a pragmatic approach, and
serum values of zero seemed unlikely. Crude and adjusted hazard ratios (HR) with 95% confi-
dence interval (CI) were estimated for RFS and OS using Cox regression. Survival curves were
estimated using the Kaplan-Meier method and equality of strata was tested for by a likelihood
ratio test. The variables included in the multivariate analyses (Tables 3 and 4) were the follow-
ing: serum values of YKL-40, IL-6, CRP, CEA, CA19-9, age, gender, location of the primary
tumor, presentation of liver metastases (synchronous/metachronous), type of liver resection
(minor/major), the number and size of the liver metastases, and the resection margins
(R0/1/2).
Proportional hazards assumption was evaluated by testing for trends in the scaled Schoen-
feld residuals. A cut point analysis was carried out for all investigated markers with regards to
their discriminatory power for 3-year mortality and 3-year recurrence using receiver operating
characteristic (ROC) curves and calculating the area under the curve (AUC). The cut point
with a sensitivity closest to 80% was chosen. All statistical analyses were carried out using the
statistical software R version 3.3.3 (R Core Team, Vienna, Austria). A p-value of less than 0.05
was considered significant, and only two-sided tests were used.
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Results
Patient characteristics and the pre- and postoperative serum concentrations of YKL-40, IL-6,
CRP, CEA, and CA19-9 are shown in Tables 1 and 2, respectively. The median age of the
patients was 64.9 years, and 59% of them were men. During the follow-up period, 265 patients
(60%) experienced a recurrence, of which 242 (91%) were diagnosed within 3 years after liver
resection. The median RFS was 1.7 years (IQR: 0.6–6.6 years). Median OS was 5.8 years (IQR:
5.4–8.4 years), and 268 patients (61%) died during follow-up. Median follow-up time was 5.7
years.
The results of the cut point analysis showed that only elevated postoperative CEA had an
AUC larger than 0.7 (AUCCEA = 0.73, 95% CI 0.66–0.79) for predicting mortality within 3
years (S1 Table and S2 Fig). Based on the cut point analyses of the markers, we chose to use the
pre-specified cut-offs as the optimal cut points did not differ markedly from them (see S1
Table–S4 Table and S1 Fig for results of the cut point analyses).
The characteristics of the pre- and postoperative biomarker values are shown in Table 2.
YKL-40 and IL-6 increased after liver resection: the median increase in YKL-40 levels was 13
ng/ml (range -1261–571, p = 0.015) and in IL-6 levels 1.7 pg/ml (range -19.4–73.9, p<0.001).
Table 1. Baseline patient characteristics and outcome data.
Variable Overall (N = 441)
Sex
Male 260 (59.0%)
Female 181 (41.0%)
Age in years, median (min.–max.) 64.9 (33–84)
Location of the primary tumor
Right colon 84 (19.0%)
Left colon 174 (39.5%)
Rectum 183 (41.5%)
Presentation of liver metastases1
Synchronous 254 (57.6%)
Metachronous 187 (42.4%)
Number of liver metastases, median (max.) 1 (16)
Size of the largest metastasis, median (max.) 2.5 cm (15.0)
Type of liver resection2:
Minor 201 (45.6%)
Major 239 (54.2%)
Missing 1
Resection margins
R0 412 (93.6%)
R1 19 (4.3%)
R2 9 (2.0%)
OS after liver resection, median (min.–max.) 5.8 years (0.0–19.7)
RFS after liver resection, median (min.–max.) 1.7 years (0.04–19.3)
Alive at the end of follow-up 172 (39.0%)
Alive without recurrence 123 (27.9%)
Recurrence or death 318 (72.1%)
1 Diagnosed within 6 months after the operation of the primary tumor (synchronous) or later (metachronous).
2 1–2 (minor) or�3 (major) Couinaud segments resected.
https://doi.org/10.1371/journal.pone.0236569.t001
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Preoperative YKL-40 correlated with preoperative IL-6 (rho = 0.39, p<0.001) and preoper-
ative CEA (rho = 0.11, p = 0.024), and postoperative YKL-40 with postoperative IL-6
(rho = 0.28, p<0.001) and postoperative CEA (rho = 0.15, p = 0.002). Preoperative CRP corre-
lated with preoperative IL-6 (rho = 0.31, p<0.001), YKL-40 (rho = 0.21, p<0.001) and CEA
(rho = 0.25, p<0.001). Preoperative CEA correlated with preoperative CA19-9 (rho = 0.41,
p<0.001) and CRP (rho = 0.25, p<0.001), and postoperative CEA with postoperative CA19-9
(rho = 0.22, p<0.001). Postoperative CA19-9 correlated with postoperative IL-6 (rho = 0.13,
p = 0.008). Age correlated with pre- and postoperative YKL-40 (rho = 0.25, p<0.001; and
rho = 0.33, p<0.001, respectively), with preoperative IL-6 (rho = 0.16, p = 0.001), and with
postoperative CA19-9 (rho = 0.11, p = 0.027). There was no significant correlation between
age and CEA.
Association of relapse-free survival with YKL-40, IL-6, CRP, CEA, and
CA19-9
The results of the univariate and multivariate analyses for RFS are shown in Table 3. All the
coefficients in the Cox regression analyses for pre- and postoperative variables in regard to
RFS and OS can be found in the S5 Table.
Higher preoperative log2-transformed YKL-40 (HR 1.19), IL-6 (HR 1.15) and CA19-9 (HR
1.08) were associated with shorter RFS in the univariate analysis, and CA19-9 in the multivari-
ate analysis (HR 1.12). Patients with 3 elevated biomarkers concurrently were at an increased
risk of relapse compared to those with no elevated biomarkers in the univariate (HR 1.60; Fig
1A) and in the multivariate analyses (HR 1.63). Patients with 2–5 elevated markers compared
to those with 0–1 had shorter RFS in univariate (HR 1.37; Fig 2A) and in multivariate (HR
1.40) analyses.
To investigate whether YKL-40, IL-6 and/or CRP drove this association, an explorative
multivariate analysis was carried out. It showed that neither preoperatively elevated CEA and/
or CA19-9 nor elevated YKL-40, IL-6 and/or CRP associated with shorter RFS (S6 Table).
Higher postoperative log2-transformed YKL-40 (HR 1.21), IL-6 (HR 1.11), CEA (HR 1.24),
and CA19-9 (HR 1.12) all were associated with shorter RFS in the univariate analyses, but CRP
Table 2. Pre- and postoperative biomarker concentrations.
Biomarker Preoperative Postoperative
YKL-40 (number) 413 413
Median (min.–max.) (ng/ml) 74 (20–1504) 87 (20–744)
Elevated (>age-corrected 95th percentile), n (%) 57 (13.8) 78 (18.9)
IL-6 (number) 413 413
Median (min.–max.) (pg/ml) 3.4 (0.3–33.5) 5.1 (0.6–80.7)
Elevated (>4.95 pg/ml), n (%) 142 (34.4) 214 (51.8)
CRP (number) 429 434
Median (min.–max.) (mg/l) <5 (<5–149) <5 (<5–153)
Elevated (>5 mg/l), n (%) 86 (20.0) 129 (29.7)
CEA (number) 440 440
Median (min.–max.) (μg/l) 5.2 (0.5–853) 2.5 (0.5–294)
Elevated (>5 μg/l), n (%) 221 (50.2) 74 (16.8)
CA19-9 (number) 437 436
Median (min.–max.) (kU/l) 13 (<2–11 310) 9 (<2–33 800)
Elevated (>37 kU/l), n (%) 99 (22.7) 43 (9.9)
https://doi.org/10.1371/journal.pone.0236569.t002
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was not. In the multivariate analysis, the association between shorter RFS and higher CEA and
CA19-9 remained statistically significant (Table 3).
The patients with 2–5 elevated biomarkers postoperatively were at an increased risk of
relapse compared to those with 0–1 elevated (HR 1.54; Figs 3A and 4A), and this association
remained statistically significant in the multivariate analysis (HR 1.57). Compared with zero
elevated biomarkers, having CEA and/or CA19-9 elevated was significantly associated with
shorter RFS, while elevated YKL-40, IL-6 and/or CA19-9 were not (S6 Table).
Association of overall survival with YKL-40, IL-6, CRP, CEA, and CA19-9
The results of the univariate and multivariate analyses are shown in Table 4.
Higher preoperative log2-transformed YKL-40 (HR 1.29), IL-6 (HR 1.16), CEA (HR 1.07),
and CA19-9 (HR 1.12) were associated with shorter OS in the univariate analyses, but CRP
Table 3. Results of the Cox regression analyses for relapse-free survival.
Univariate p-value Multivariate1 p-value
HR (95% CI) HR (95% CI)
Preoperatively measured biomarkers
YKL-40 1.19 (1.07–1.32) <0.001 1.08 (0.96–1.22) 0.212
IL-6 1.15 (1.03–1.28) 0.010 1.04 (0.91–1.18) 0.566
CRP 1.08 (0.96–1.21) 0.219 1.03 (0.88–1.20) 0.756
CEA 1.01 (0.96–1.07) 0.583 1.00 (0.93–1.07) 0.952
CA19-9 1.08 (1.03–1.14) <0.001 1.12 (1.06–1.19) <0.001
0 elevated (N = 111) Reference Reference
1 elevated (N = 113) 0.81 (0.58–1.12) 0.202 0.81 (0.58–1.12) 0.202
2 elevated (N = 101) 1.13 (0.83–1.56) 0.438 1.21 (0.87–1.68) 0.252
3 elevated (N = 44) 1.60 (1.08–2.36) 0.018 1.63 (1.08–2.47) 0.021
4 elevated (N = 29) 1.57 (0.99–2.49) 0.055 1.88 (1.12–3.16) 0.016
5 elevated (N = 1) 2.86 (0.40–20.7) 0.298 3.60 (0.48–26.8) 0.211
0–1 elevated (N = 224) Reference Reference
2–5 elevated (N = 175) 1.37 (1.10–1.72) 0.005 1.40 (1.11–1.78) 0.005
Postoperatively measured biomarkers
YKL-40 1.21 (1.09–1.34) <0.001 1.06 (0.94–1.19) 0.323
IL-6 1.11 (1.01–1.23) 0.033 0.98 (0.87–1.11) 0.755
CRP 1.07 (0.99–1.15) 0.075 1.02 (0.92–1.12) 0.741
CEA 1.24 (1.14–1.34) <0.001 1.17 (1.07–1.29) <0.001
CA19-9 1.12 (1.04–1.20) 0.002 1.09 (1.01–1.17) 0.029
0 elevated (N = 137) Reference Reference
1 elevated (N = 99) 1.18 (0.87–1.62) 0.290 1.00 (0.73–1.38) 0.993
2 elevated (N = 106) 1.41 (1.05–1.91) 0.023 1.30 (0.95–1.78) 0.102
3 elevated (N = 48) 1.98 (1.37–2.86) <0.001 1.84 (1.25–2.71) 0.002
4 elevated (N = 10) 2.94 (1.48–5.86) 0.002 2.50 (1.22–5.12) 0.012
5 elevated (N = 3) 3.67 (1.16–11.7) 0.028 3.14 (0.97–10.1) 0.055
0–1 elevated (N = 236) Reference Reference
2–5 elevated (N = 167) 1.54 (1.23–1.92) <0.001 1.57 (1.24–1.98) <0.001
1 Variables included in the multivariate analyses: serum values of IL-6, YKL-40, CRP, CEA, and CA19-9; age; gender; location of the primary tumor; type of liver
metastases (synchronous/metachronous; Table 1); type of liver resection (minor/major; Table 1); the number and size of the liver metastases; and the resection margins
(R0/1/2). The biomarkers are presented as log2-transformed continuous variables.
https://doi.org/10.1371/journal.pone.0236569.t003
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was not. Higher YKL-40 and CA19-9 remained significant in the multivariate analysis (HR
1.19, and HR 1.13, respectively).
The patients with 2–5 elevated biomarkers preoperatively were at an increased risk of death
compared to those with 0–1 elevated biomarkers (HR 1.76; Figs 1B and 2B), and this associa-
tion remained statistically significant in the multivariate analysis (HR 1.71). Neither preopera-
tively elevated CEA and/or CA19-9 nor elevated YKL-40, IL-6 and/or CRP associated
significantly with shorter OS, when taken in combination (S6 Table).
Higher postoperative log2-transformed values of all biomarkers associated with shorter OS
in the univariate analyses (YKL-40: HR 1.26; IL-6: HR 1.13; CRP: HR 1.11; CEA: HR 1.33; and
CA19-9: HR 1.22), and CEA (HR 1.24) and CA19-9 (HR 1.17) remained significant in the
multivariate analysis (Table 4).
Fig 1. Kaplan-Meier curves showing the associations between the numbers of elevated preoperative biomarkers and (A) relapse-free survival and (B) overall survival.
https://doi.org/10.1371/journal.pone.0236569.g001
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The patients with 2–5 elevated biomarkers postoperatively were at an increased risk of
death compared to those with 0–1 elevated (HR: 1.83; Figs 3B and 4B). In the multivariate
analysis, this association remained significant (HR 1.84). Compared with zero elevated bio-
markers, having CEA and/or CA19-9 elevated was significantly associated with shorter OS,
while elevated YKL-40, IL-6 and/or CA19-9 were not (S6 Table).
Discussion
In this biomarker study of patients with colorectal liver metastases, we found that higher
serum values of YKL-40 and CA19-9 preoperatively were associated with shorter OS.
Similar results were found for postoperatively higher serum values of CEA and CA19-9
Fig 2. Kaplan-Meier curves showing the associations between 0–1 and 2–5 elevated preoperative biomarkers and (A) relapse-free survival and (B) overall survival.
https://doi.org/10.1371/journal.pone.0236569.g002
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postoperatively. Interestingly, we found that patients with two or more elevated biomarkers
pre- or postoperatively had a shorter OS, suggesting that a combined panel of inflammatory
biomarkers could be used in combination with the tumor biomarkers CEA and CA19-9.
Higher serum values of YKL-40 and CA19-9 preoperatively and higher serum values of CEA
and CA19-9 postoperatively associated with shorter RFS, and a combination of all the bio-
markers showed that patients with two or more elevated biomarkers postoperatively had a
shorter RFS. No previous studies have evaluated the combined prognostic value of these 5
biomarkers.
Our results are in line with recent studies examining the prognostic value of serum YKL-40
[26], CEA [8, 9, 27, 28], and CA19-9 [8, 9, 27] as biomarkers in patients with mCRC. CRP
has recently been found to have prognostic value in patients with mCRC, although our results
Fig 3. Kaplan-Meier curves showing the associations between the numbers of elevated postoperative biomarkers and (A) relapse-free survival and (B) overall survival.
https://doi.org/10.1371/journal.pone.0236569.g003
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do not directly support this finding [29]. The association between serum IL-6 and OS in
patients with CRC is unclear, since some previous studies have found higher IL-6 levels to be
significantly associated with shorter OS, while others have failed to show any association [16,
29, 30]. We did not find a direct association between IL-6 and RFS or OS, when adjusted for
other biomarkers.
YKL-40 has recently been found to be involved in the formation of cancer metastases
through regulation of epithelial to mesenchymal transformation and subsequent migration/
invasion [31]. In addition, YKL-40 has been shown to regulate VEGF in tumor cells and to
promote angiogenesis, enabling tumors to spread via a hematological pathway [12]. This may
explain why we see high serum YKL-40 levels in patients with mCRC and, furthermore, why
high serum YKL-40 seems to reflect relapse after liver resection. In a recent study it was shown
Fig 4. Kaplan-Meier curves showing the associations between 0–2 and 2–5 elevated postoperative biomarkers and (A) relapse-free survival and (B) overall survival.
https://doi.org/10.1371/journal.pone.0236569.g004
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that paracrine signaling of IL-6 in synergy with IL-8 directly promoted cell migration and is
thus important in the formation of metastasis [32]. Recently, IL-6 has also been found to be
involved in the formation of a metastatic niche in the liver [33], which indicates that it could
be associated with a negative outcome in CRC. The symptoms of inflammation, i.e. sarcopenia
and cachexia, that accompany many cancers may be related to higher IL-6 levels in serum, and
they are presently being investigated relative to treatment efficacy also in mCRC [34]. One
option that has been suggested is treatment with the monoclonal antibody tocilizumab, which
targets the IL-6 receptor, given in combination with standard chemotherapy in other indica-
tions [35, 36].
The reason for investigating IL-6, CRP and YKL-40 in combination, in spite of the fact that
IL-6 primarily stimulates YKL-40 and the production of CRP in the liver [14], is that YKL-40
is also stimulated by other biological processes and proinflammatory cytokines [12]. In addi-
tion, we can assume that the production of CRP is affected by liver metastases. This makes
Table 4. Results of the Cox regression analyses in relation to overall survival.
Univariate p-value Multivariate1 p-value
HR (95% CI) HR (95% CI)
Preoperatively measured biomarkers
YKL-40 1.29 (1.16–1.44) <0.001 1.19 (1.04–1.35) 0.010
IL-6 1.16 (1.03–1.30) 0.011 1.03 (0.90–1.18) 0.685
CRP 1.07 (0.95–1.21) 0.240 0.91 (0.77–1.06) 0.215
CEA 1.07 (1.01–1.12) 0.019 1.02 (0.95–1.09) 0.602
CA19-9 1.12 (1.06–1.18) <0.001 1.13 (1.06–1.20) <0.001
0 elevated (N = 111) Reference Reference
1 elevated (N = 113) 0.86 (0.60–1.24) 0.433 0.82 (0.57–1.18) 0.284
2 elevated (N = 101) 1.63 (1.16–2.30) 0.005 1.58 (1.11–2.24) 0.011
3 elevated (N = 44) 1.82 (1.19–2.79) 0.006 1.60 (1.02–2.50) 0.042
4 elevated (N = 29) 1.78 (1.08–2.93) 0.023 1.75 (1.01–3.04) 0.046
5 elevated (N = 1) 3.24 (0.45–23.5) 0.245 2.90 (0.39–21.7) 0.299
0–1 elevated (N = 224) Reference Reference
2–5 elevated (N = 175) 1.76 (1.39–2.24) <0.001 1.71 (1.33–2.21) <0.001
Postoperatively measured biomarkers
YKL-40 1.26 (1.13–1.41) <0.001 1.10 (0.97–1.24) 0.131
IL-6 1.13 (1.02–1.26) 0.022 0.95 (0.83–1.09) 0.498
CRP 1.11 (1.02–1.20) 0.011 1.09 (0.99–1.20) 0.096
CEA 1.33 (1.22–1.46) <0.001 1.24 (1.12–1.36) <0.001
CA19-9 1.22 (1.13–1.31) <0.001 1.17 (1.08–1.28) <0.001
0 elevated (N = 137) Reference Reference
1 elevated (N = 99) 1.03 (0.72–1.47) 0.882 0.88 (0.61–1.27) 0.488
2 elevated (N = 106) 1.57 (1.13–2.17) 0.007 1.40 (0.99–1.97) 0.055
3 elevated (N = 48) 2.42 (1.64–3.56) <0.001 2.33 (1.56–3.48) <0.001
4 elevated (N = 10) 4.45 (2.21–8.96) <0.001 4.42 (2.16–9.05) <0.001
5 elevated (N = 3) 10.2 (3.16–32.9) <0.001 8.91 (2.71–29.2) <0.001
0–1 elevated (N = 236) Reference Reference
2–5 elevated (N = 167) 1.83 (1.44–2.33) <0.001 1.84 (1.43–2.37) <0.001
1 Variables included in the multivariate analyses: serum values of IL-6, YKL-40, CRP, CEA, and CA19-9; age; gender; location of the primary tumor; type of liver
metastases (synchronous/metachronous; Table 1); type of liver resection (minor/major; Table 1); the number and size of the liver metastases; and the resection margins
(R0/1/2). The biomarkers are presented as log2-transformed continuous variables.
https://doi.org/10.1371/journal.pone.0236569.t004
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studying all biomarkers in our patient cohort interesting, as the normal pathways may be inter-
rupted by the pathophysiology of the metastases. Our results show that while there are clear
associations between the studied inflammatory biomarkers, YKL-40 in particular seems to be
singularly associated with RFS, which cannot be accounted for by IL-6. Several studies have
shown an association between high serum YKL-40 and IL-6 and shorter OS in different types
of cancers and in patients with severe inflammatory diseases [12, 37, 38], which limits their
specificity. In addition, serum YKL-40 has been shown to be increased until the 21st postopera-
tive day merely due to the surgical trauma related to primary tumor resection [39]. We sam-
pled blood a median of 94 (IQR 89–98) days after surgery. Thus, the postoperative increase
seen in serum YKL-40 and IL-6 in some of the patients could be caused by micro-metastatic
disease rather than the large surgical trauma in the liver, although it is possible that some effect
of the surgical trauma persisted. We assume that the postoperative changes in inflammatory
biomarkers would have normalized before the postoperative sampling.
Elevated postoperative CEA was associated with shorter RFS and OS, as has also been
found in previous studies [9, 28]. A systematic review by Spelt et al. [40] showed a large varia-
tion in cut-off values and in the prognostic value of CEA measured before liver resection for
CRLM, which naturally leads to the conclusion that different cut-off values may influence the
results. We used a cut-off value of 5 μg/l since higher cut-offs have no impact on sensitivity in
our cut-point analysis.
High preoperative and postoperative CA19-9 associated with poor prognosis, which is in
line with previous studies [8, 9, 27, 28]. Despite these findings, the role of adding CA19-9 to
CEA in the follow-up of CRC patients has not yet been established. Our results strengthen the
importance of CA19-9 as a prognostic and predictive marker in mCRC.
In our explorative analysis, further investigating the observed enhanced risk of relapse or
death when having an increased number of elevated markers, it seemed that CA19-9 and CEA
were the main drivers of the association. These biomarkers were also more consistently associ-
ated with a negative outcome, when analyzed on a continuous scale. We acknowledge that the
use of 2–5 elevated biomarkers is non-specific, but it suggests which combinations of markers
most reliably predict the outcome of patients. The additive value of the inflammatory markers
to a standard biomarker may thus be limited, but they could identify selected patients, since
the risk of relapse or death increases with each additional elevated marker. Further research
will be needed to elucidate this aspect, and we are aware that the added value of IL-6 and CRP
is limited in the present study.
It is probable that new technologies, liquid biopsies in particular, will be applied to clinical
use quite shortly. They have potential in the detection and management of CRC, as they offer a
non-invasive method for early detection of cancer, prognostic and predictive information,
monitoring of treatment response, and identification of minimal residual disease [41]. In con-
junction with resection of CRLM, elevated pre- [42] and postoperative [43] ctDNA levels have
shown high concordance with relapse in ctDNA-positive patients. However, it seems unlikely
that liquid biopsies could provide information on inflammatory responses, which affect the
prognosis of CRC. Thus, the inflammatory biomarkers have an important role also in this era
of advances in these new technologies.
A limitation of our study is the lack of a validation cohort. We did not consider the diurnal
variation of IL-6 [44], which may confound our results. It would also be interesting to study
the value of YKL-40, IL-6, CRP, CEA and CA19-9 in consecutive blood samples after surgery
to see whether repeated measurements give more information on the patients’ prognoses and
lead-time to relapse. We did not adjust for multiple testing by for example Bonferroni-Holm
correction of p-values. This represents a drawback of the study and limits the confidence in
our findings. The strengths of our study are the fairly large number of consecutive patients
PLOS ONE YKL-40, IL-6, CRP, CEA, and CA19-9 as prognostic biomarkers after resection of colorectal liver metastases
PLOS ONE | https://doi.org/10.1371/journal.pone.0236569 August 5, 2020 13 / 18
included, the long follow-up time, and the reliable follow-up data with no patients lost to fol-
low-up. Information about the KRAS, NRAS and BRAF mutational status as well as the micro-
satellite instability (MSI) status could have been valuable, since the mutational status has been
shown to predict recurrence patterns after liver resection [45, 46], but the mutational status
was not routinely analyzed at Helsinki University Hospital prior to 2013 and the MSI not prior
to 2018.
Conclusions
Pre- and postoperative serum levels of a panel of three inflammatory biomarkers YKL-40, IL-
6, and CRP with the two cancer biomarkers CEA and CA19-9 showed that the patients with 2
or more elevated biomarkers had shorter RFS and OS after resection of liver metastases. In the
future, this panel might be used to select the patients that could benefit from more aggressive
perioperative chemotherapy and follow-up, although the role of IL-6 and CRP needs to be
explored further.
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